共查询到20条相似文献,搜索用时 203 毫秒
1.
目的 探讨可溶性白细胞介素2受体(sIL-2R)在原发性肝癌(PLC)患者中的临床意义。方法 采用双抗体夹心ELISA法检测对照组40例,健康献血员和疾病组105例PLC患者血清sIL-2R水平(其中Ⅰ、Ⅱ、Ⅲ期肝癌患者分别为22例、41例、42例)以及18例切除肿瘤后和18例栓塞化疗(TAE)后动态检测观察。结果 PLC患者血清sIL-2R水平依次增高(P〈0.01);sIL-2R水平〉1000 相似文献
2.
胃癌患者中sIL—2R表达的临床意义 总被引:3,自引:0,他引:3
采用ELISA法检测52例胃癌患者及20例健康人的血清sIL-2R浓度,结果发现:胃癌患者血清sIL-2R水平明显高于健康对照组(P〈0.01)。伴有转移者的sIL-2R升高更明显,与无转移者相比,差异显著(P〈0.01),胃癌术后sIL-2R升高提示有复发可能。 相似文献
3.
用双抗体夹心ELISA方法动态监测46例恶性淋巴瘤(ML)患者脑脊液(CSF)中可溶性白细胞介素2受体(sIL-2R)水平变化。发现ML患者脑脊液中sIL-2R比正常人显著升高(P〈0.001),且6例有中枢神经系统(CNS)浸润者sIL-2R与无CNS浸润者相比有显著性差异(P〈0.01);而治疗达CR或PR后sIL-2R显著降低(P〈0.05),与正常人者相比P〉0.05,脑脊液sIL-2R水 相似文献
4.
应用双抗体夹心ELISA方法测定了30例喉癌患者血清可溶性白细胞介素2受体(sIL-2R)水平。结果表明:喉癌患者血清sIL-2R水平明显高于正常人(P〈0.01);与临床分期有关,病期越晚,sIL-2R水平越高;sIL-2R水平超过1000U/ml者,多预后不良;9例术后2 ̄8月再次采血检验,6例无癌生存者sIL-2R水平明显下降(P〈0.01),3例复发的患者血清sIL-2R升高。提示:喉癌患 相似文献
5.
应用双抗体夹心ELISA方法测定了30例喉癌患者血清可溶性白细胞介素2受体(SIL-ZR)水平。结果表明:喉癌患者血清SIL-ZR水平明显高于正常人(P<0.01);与临床分期有关,病期越晚,sIL-2R水平越高;sIL-2R水平超过1000U/ml者,多预后不良;9例术后2~8月再次采血检验,6例无癌生存者sIL-2R水平明显下降(P<0.01),3例复发的患者血清sIL-2R升高。提示:喉癌患者血清sIL-2R的测定对预后判断和疗效观察有重要意义。 相似文献
6.
本文应用双抗体夹心直接ELISA法对36例胃癌患者血清SIL-2R水平进行了测定。胃癌患者血清SIL-2R水平明显高于正常人群(P〈0.01)及慢性良性胃病患者(P〈0.001);Ⅲ-Ⅳ期患者血清SIL-2R水平明显高于Ⅰ-Ⅱ期患者(P〈0.01):胃癌根治后10天血清SIL-2R水平较术前明显下降(P〈0.01),与正常人群对照无明显差异(P〈0.05)。结果说明血清SIL-2R测定可作为胃癌的 相似文献
7.
通过采用sIL-2R单克隆抗体(McAb)建立了可溶性IL-2R(sIL-2R)的双夹心ELISA法,检测了161倒Ⅲ~Ⅳ期胃癌患者在手术前后、复发或转移及80例单纯化疗后血清中sIL-2R变化。结果表明:晚期胃癌患者血清中sIL-2R水平显著高于正常人(P<0.01),在有转移或术后复发时,sIL-2R水平显著升高,sIL-2R<1000U/ml患者三年生存率显著高于>1000U/ml者;化疗有效者,sIL-2R可明显下降,无效者则无明显改变,提示晚期胃癌患者sIL-2R水平对判断预后有重要临床价值。 相似文献
8.
目的 探讨检测血清可溶性白细胞介素2受体(SIL-2R)和肺癌组织IL-2R表达在非小细胞肺癌中的临床意义。方法 采用双抗体夹心ELISA法和免疫组化法检测42例非小细胞肺癌患者血清和肺癌组织中IL-2R水平。结果 肺癌患者血清SIL-2R水平显著高于正常人(P〈0.05),Ⅲ,Ⅳ期肺癌患者血清SIL-2R水平显著高于Ⅰ,Ⅱ期(P〈0.05),但血清SIL-2R水平与肺癌组织学类型无明显关系(P〉 相似文献
9.
制备了人IL-2RacDNA探针,采用斑点印迹杂交法对46例肺癌患者外周血单个核细胞(PBMC)IL-2RmRNA的表达水平进行研究。结果发现IL-2RmRNA的表达程度与肿瘤转移关系密切。肺癌无转移组:IL-2RmRNA表达显著高于对照组与转移组(P<0.001),且与患者的组织学类型及病期有明显关系。转移组:IL-2R表达显著低于对照组(P<0.001),提示此组病人存在免疫抑制.其抑制可能存在细胞活化阶段或IL-2R的转录水平。同期所测血清肿瘤坏死因子(TNF)在两组患者无明显差异。本组结果提示:IL-2RmRNA表达水平与患者预后密切相关。 相似文献
10.
11.
大肠癌患者血清IAP、sIL-2R和IL-12变化 总被引:4,自引:0,他引:4
[目的]探讨检测血清IAP、sIL鄄2R和IL鄄12含量在大肠癌的辅助诊断、预后判断中的临床意义。[方法]采用单向免疫扩散法和ELISA法分别检测30例健康正常人及32例大肠癌患者手术前、后的血清IAP、sIL鄄2R和IL鄄12水平。[结果](1)大肠癌患者手术前血清IAP、sIL鄄2R水平均明显高于对照组(P<0.001和P<0.01),晚期组血清IAP、sIL鄄2R水平明显高于早期组(P<0.02和P<0.05),IAP与sIL鄄2R水平呈显著正相关(r=0.987,P<0.001);大肠癌患者血清IL鄄12水平明显低于对照组(P<0.05)。(2)串联IAP、sIL鄄2R两指标筛检大肠癌的敏感性为78.1%,特异性为93.33%,并联两指标筛检大肠癌,其敏感性为93.75%,特异性为73.3%。(3)手术后患者血清IAP、sIL鄄2R水平均明显低于手术前(P<0.001),早期组下降有明显差异性(P<0.001),而晚期组下降不明显(P>0.1);患者术后血清IL鄄12水平明显比术前升高(P<0.02),早期组上升显著(P<0.001),晚期组上升不明显(P>0.05)。[结论](1)检测患者血清IAP、sIL鄄2R水平对大肠癌的辅助诊断、病情判断、手术治疗和预后观察均有较高的临床价值。(2)联合检测血清IAP、sIL鄄2R对筛检大肠癌患者具有较高的敏感性。(3)血清IAP、sIL鄄2R和IL鄄12可作为指导大肠癌患者免疫学治疗较客观的指标。 相似文献
12.
目的:研究结直肠癌(colorectal carcinoma,CRC)患者血清中白细胞介素17(interleukin 17,IL-17)和IL-6的表达,探讨IL-17和IL-6与CRC发生和发展之间的关系.方法:采用ELISA方法检测56例CRC患者和30例健康志愿者(对照组)血清IL-17和IL-6的变化,分析IL-17和IL-6与CRC患者各临床病理特征之间的关系.结果:56例CRC患者血清IL-17为96.43±21.15 ng/L,IL-6为139.53±27.84 ng/L,均明显高于对照组(IL-17为16.88±5.07 ng/L,IL-6为39.21±7.46 ng/L,P<0.01);IL-17和IL-6水平的上升与患者的性别和年龄无关(P>0.05),而与肿瘤的大小、远处转移、Dukes分期及病理组织学分型明显相关(P<0.01).结论:CRC患者血清中IL-17和IL-6水平随着肿瘤的进展而明显上升,预示IL-17和IL-6直接或间接参与了CRC的发生和发展. 相似文献
13.
采用双抗体夹心ELlSA法检测43例原发性肝细胞癌(PHC)病人血清可溶性白细胞介素2受体(sIL-2R)水平,及其外周血单个核细胞(PBMC_s)的白细胞介素2(IL—2)活性和自然杀伤(NK)细胞活性.另将51例慢性乙型活动性肝炎和肝硬化病人做为对照.结果,上述病人血清sIL—2R水平明显升高,IL—2和 NK活性低于正常人,其中PHC的IL—2和NK活性的降低又为显著(P<0.001< O.001).表明PHC病人的细胞免疫功能受损程度最重.检测sIL_2R水平和IL—2活性,可望做为对PHC患者病情分析及判断预后的指标. 相似文献
14.
目的:为了比较不同阶段多发性骨髓瘤(MM)病人血清IL-6及可溶性受体sIL-6R水平与疾病活动性及预后之间的关系。方法;对16名良性骨肿瘤病人,15名多发性骨髓瘤稳定期病人,29名MM进展期及正常人之间血清IL-6,sIL-6R水平进行了比较,采用ELISA方法测定浓度水平,两组间差异采用t检验方法。结果:两指标在各组间存在明显的差异(P<0.05),同时,在对29名多发性骨髓瘤的随访治疗过程中,18名有效病人的IL-6,sIL-6R在治疗前后存在明显差异,而在无效和死亡的病人中,治疗前后无明显差别。结论:IL-6及sIL-6R水平与疾病的严重程度密切相关,可作为判断病情和预后的一项重要参数。 相似文献
15.
氟达拉滨对多发性骨髓瘤细胞系KM3细胞分泌IL-6的影响 总被引:1,自引:0,他引:1
目的:研究氟达拉滨(fludarabine)在体外对多发性骨髓瘤细胞KM3细胞生长的影响及对细胞上清液IL-6、sIL-6R的影响。方法:采用MTT法及细胞计数法分别观察不同浓度氟达拉滨对KM3细胞生长的影响;用双抗夹心法检测不同浓度氟达拉滨作用KM3细胞后上清液白细胞介素6(interleukin-6,IL-6)和可溶性白细胞介素6受体(soluble interleukin-6 receptor,sIL-6R)的表达水平。结果:MTT法及细胞计数法均显示氟达拉滨对KM3细胞有明显的抑制作用,氟达拉滨作用KM3细胞72h后,25、50、100、200、400nmol/L组的增殖抑制率均高于对照组(P〈0.01),且与浓度成正比。400nmol/L组对KM3细胞增殖抑制率随时间的延长而增加。双抗夹心法检测结果显示KM3细胞经氟达拉滨作用96h后,其IL-6水平先升高后明显下降,而sIL-6R水平随药物浓度的升高而逐渐下降。结论:氟达拉滨能明显抑制KM3细胞的增殖,同时能抑制KM3细胞自分泌IL-6和sIL-6R。 相似文献
16.
Serum Levels of Interleukin-8 and Soluble Interleukin-6 Receptor in Patients with Stage-I Multiple Myeloma: A Case-Control Study
下载免费PDF全文
![点击此处可从《Asian Pacific journal of cancer prevention》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Maryam KohsariMohammad-Hassan Khadem-AnsariYousef RasmiHojjat Sayyadi 《Asian Pacific journal of cancer prevention》2020,21(1):127-132
Objective: Multiple myeloma (MM) remains an incurable disease that needs better recognition and further research. Previous studies elucidated the interaction between myeloma cells and showed the necessity of bone marrow stromal cells for the initiation and progression of MM. Many chemokines and their receptors including interleukin-8 (IL-8) and soluble interleukin-6 receptor (sIL-6R) play important roles in this interaction. The main purpose of this study is evaluating the serum level of IL-8 and sIL-6R on stage-I of MM patients and healthy controls. Methods: Serum samples from 30 stage-I MM patients (13 males and 17 females) and 30 healthy subjects as controls (13 males and 17 females) were examined in this study. The protein concentrations of serum IL-8 and sIL-6R were assessed by enzyme-linked immunosorbent assay (ELISA). Results: The mean level of IL-8 and sIL-6R were significantly elevated in stage-I MM. The mean levels of IL-8 were 1246.57±279.22 ng/ml in stage-I MM and 902.53± 294.61 ng/ml in controls (P<0.001). The mean levels of sIL-6R were 5.39±1.38 ng/ml and 4.1±1.14 ng/ml in stage-I MM and controls, respectively (P<0.001). The mean levels of IL-8 were 1342.18±193.4 ng/ml in patient females and 859± 278.2ng/ml in control females (P <0.001). The mean levels of sIL-6R were 5.21±1.55 ng/ml and 3.91±1.22 ng/ml in patient females and control females, respectively (P=0.01). The mean level of sIL-6R in patient males and control males were 5.63±1.43 ng/ml and 4.34±1.04 ng/ml, respectively (P=0.01). A significant correlation (Pearson’s correlation = 0.45, P=0.008) was observed in the population of females (patients and controls). Conclusion: The results of study suggest the possible involvement of IL-8 and the sIL-6R at stage-I MM and can better characterize the role of chemokines and their receptors in the disease process, especially in the early stages. 相似文献
17.
Doç. Dr. Murat Soker Leyla Çolpan Aydin Ece Celal Devecioğlu Kenan Haspolat 《Medical oncology (Northwood, London, England)》2001,18(1):51-57
Serum levels of interleukin-1 beta (IL-1beta), soluble interleukin 2 receptors (sIL-2R), interleukin-6 (IL-6), interleukin-8 (IL-8), and tumor necrosis factor-alpha (TNF-alpha) were measured to predict some characteristics of febrile episodes in children with cancer and neutropenia. Forty-eight episodes of febrile neutropenia were determined in 23 pediatric cancer patients, including 35 febrile episodes without identifiable source, 7 episodes of bacteremia due to Gram-negative organisms and 4 due to Gram-positive organisms, and 2 fungal infections. Interleukin-6, sIL-2R, and IL-8 levels were significantly higher at the beginning of the febrile episodes than those of controls (p < 0.001, p < 0.001, and p < 0.001). Interleukin-6, slL-2R, and IL-8 levels were higher in patients with bacteremia due to Gram-negative organisms than in those with Gram-positive ones (p = 0.042, p = 0.006, and p = 0.023, respectively). TNF-alpha and IL-1beta levels were similar in febrile episodes and controls (p > 0.05). In conclusion, sIL-2R, IL-6, and IL-8 levels may be helpful in the prediction of infection in febrile cancer patients with neutropenia and measurements of IL-1beta and TNF-alpha were not useful for identifying the presence and the type of infection in febrile neutropenic episodes in children. 相似文献
18.
目的:探讨皮肤T细胞淋巴瘤(CTCL)患者外周血淋巴细胞亚群及血清可溶性白细胞介素2受体(sIL-2R)、炎性因子的水平变化特点及意义。方法:选取2013年1月至2018年1月在我院治疗的CTCL患者35例(CTCL组),同时选取炎症性皮肤病患者35例作为对照组,检测两组血清sIL-2R、B淋巴细胞、T淋巴细胞和NK细胞水平以及白细胞介素-6(IL-6)、肿瘤坏死因子 (TNF-α)和C反应蛋白(CRP)。结果:CTCL组血清sIL-2R为(770.15±87.44)U/ml,明显高于对照组(P<0.05),而B淋巴细胞为6.10(0.15~10.57)%,明显低于对照组(P<0.05);CTCL组和对照组T淋巴细胞和NK细胞比较差异无统计学意义(P>0.05);CTCL组血清IL-6、TNF-α和CRP分别为110.02(67.39,230.03)pg/ml、(31.29±7.28)pg/ml和(36.60±6.10)mg/L,明显高于对照组(P<0.05);皮损改善患者治疗后sIL-2R为(230.04±78.11)U/ml,明显低于皮损未改善患者(P<0.05)。结论:CTCL患者血清sIL-2R、IL-6、TNF-α和CRP升高,而B淋巴细胞水平降低,其中sIL-2R与治疗效果有一定关系,值得进一步研究。 相似文献
19.
目的:探讨急性髓系白血病(AML)患者化疗后粒细胞缺乏发热时血清白细胞介素8(IL-8)和白细胞介素6(IL-6)水平与感染的关系。方法:采用双抗体夹心酶联免疫吸附法(ELISA)检测42例AML患者和20名正常对照者血清IL-8、IL-6水平。结果:血清IL-8和IL-6水平在AML患者发热第1天均升高,其中病原学检查阳性组显著高于原因不明发热组(P均<0.002)和仅有临床感染证据组(P均<0.05),仅有临床感染证据组也较原因不明发热组增高(P均<0.02),且革兰氏阴性菌感染者较革兰氏阳性菌感染者增高明显(P均<0.01);IL-8和IL-6呈显著正相关(r=0.841,P<0.001),并均与体温呈正相关(r=0.447和0.570,P<0.005和P<0.001);并发败血症死亡患者的血清IL-8、IL-6水平呈持续增高。结论:应用夹心法ELISA联合检测血清IL-8、IL-6水平,将有助于确定AML患者化疗后粒细胞缺乏发热时的早期感染及其严重性。 相似文献
20.
Prognostic value of serum biological markers in patients with hepatocellular carcinoma. 总被引:17,自引:0,他引:17
R Parasole F Izzo F Perrone S Pignata M G Galati E Leonardi F Castiglione R Orlando G Castello G Esposito C Gallo B Daniele 《Clinical cancer research》2001,7(11):3504-3509
PURPOSE: Prognosis of patients with hepatocellular carcinoma (HCC) is assessed by using indexes based on clinical and instrumental parameters. The Cancer of the Liver Italian Program (CLIP) staging system combines the Child-Pugh classification with tumor size, portal invasion, and alpha-fetoprotein and predicts the outcome of HCC patients more precisely than the Okuda staging system. Serum levels of a number of biological variables have been found to be increased in patients with HCC and are associated with different outcomes. Our aims in this study were to test the prognostic role of the serum levels of soluble intercellular adhesion molecule-1 (sICAM-1), soluble interleukin-2 receptor (sIL-2R), interleukin 6 (IL-6), and anti-p53 and to assess whether the addition of any of the above serum markers could further improve the predictive ability of the CLIP score. EXPERIMENTAL DESIGN: Serum levels of sICAM-1, sIL-2R, IL-6, and anti-p53 were assayed in 80 patients with HCC and correlated with their outcomes. Nonparametric procedures were applied to test correlations between serum sICAM-1, sIL-2R, IL-6, anti-p53, and other prognostic factors. For survival analyses, the product-limit method, log-rank test, and Cox proportional hazards model were applied. RESULTS: Only serum levels of sIL-2R correlated with survival, which was longer for patients with lower values (< or =950 units/ml). However, with multivariate analysis sIL-2R did not confirm its predictive role when tested with the CLIP score as a covariate, with a hazard of death of 1.51 (95% confidence interval, 0.76-3.01). CONCLUSIONS: Serum levels of sICAM-1, sIL-2R, IL-6, and anti-p53 are not useful as prognostic factors for HCC in clinical practice. They do not improve the predictive ability of the CLIP score. 相似文献